Views
8 years ago

Psicofarmacología 81

  • Text
  • Antenatal
  • Tratamiento
  • Embarazo
  • Tratemiento
  • Diagnostico
  • Prevalencia
  • Mayores
  • Temporal
  • Emocional
  • Neuronales
  • Rumiacion
  • Cognitivo
  • Depresion
Revista Latinoamericana de Psicofarmacología y Neurociencia.

Dra. Silvina Mazaira the

Dra. Silvina Mazaira the risk of major malformations: a systematic review. Hum Psychopharmacol Clin Exp 2007; 22: 121 – 128. 9- Bérard A, Ramos E, Rey E, Blais L, St.André M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Def Res (Part B) 2007; 80: 18 – 27. 10- Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate´s clinical presentation after in utero expossure to antidepressants in late pregnancy. J Clin Psychopharmacol 2008; 28: 334 – 339. 11- Brand S, Brennan P. Impact of antenatal and postpartum maternal mental illness: how are the children? Clin Obstet Gynecol 2009; 52: 441 – 455. 12- Burt V, Hendrick V. Clinical manual of women´s mental health. American Psychiatric Publishing Inc, Arlington, USA, 2005. 13- Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychitar Sandinav 2013; 127: 94 – 114. 14- Casper R, Fleisher B, Lee-Ancajas J, Gilles A, Gaylor E et al. Follow up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatrics 2003; 142: 402 – 408. 15- Chambers C, Hernández-Díaz S, Van Marter L, Werler M, Louik C, Lyons Jones K, Mitchell A. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579 – 587. 16- Cohen L, Altshuler L, Harlow B, Nonacs R, Newport J, Viguera A et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499 – 507. 17- Cole J, Ephross S, Cosmatos I, Walker A. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiology and Drug Safety 2007; 16: 1075 – 1085. 18- Diego M, Field T, Hernández Reif M, Schanberg S, Kuhun C, et al. Prenatal depression restricts fetal growth. Early Hum Dev 2009; 85: 65 – 70. 19- Einarson A, Koren G. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations. Canadian Family Physician 2006; 52: 593 – 594. 20- Einarson A, Pistelli A, DeSantis M, Malm H, Paulus W, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749 – 752. 21- Einarson A. Risks / safety of psychothropic mediacation use during pregnancy. Can J Clin Pharmacol 2009; 16 (1): e58 – e65. 22- Einarson A. The importance of critical evaluation of the literature regarding safety of antidepressant use in pregnancy. Acta Psychiatr Scand 2013: 127: 115–116. 23- Fall A, Goulet L, Vézina M. Comparative study of major depressive symptoms among pregnant women by employment status. SpringerPlus 2013; 2 (201). 24- Ferreira E, Carceller A, Agogué C, Martin B, St-André M, Francoeur D et al. Effects of selective serotonine reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119: 52 – 59. 25- Fleschler R, Peskin M. Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: a review. MCN 2008; Nov/Dec: 355 – 361. 26- Fransson E, Ortenstrand A, Hjelmstedt A. Antenatal depressive symptoms and preterm birth: a prospective study of a swedish national sample. Birth 2011; 38: 10 – 16. 27- Gentile S, Bellantuonno C. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry 2009; 70 (3): 414 – 422. 28- Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: A systematic review. J Affect Disord 2011; 128: 1 – 9. 29- Gentile S. Use of escitalopram during pregnancy. Navigating towards international guidelines and the real world. Clin Drug Invest 2008; 28 (11): 735 – 739. 30- Glaxo Smithkline Inc. New safety information regarding paroxetine (Paxil). September 2005. 31- Goodman S. Depression in mothers. Annu Rev Clin Psychol 2007; 3: 107 – 135. 32- Greene M. Teratogenicity of SSRIs . Serious concern or much ado about little? N Engl J Med 2007; 356:26: 2732 -2733. 33- Grigoriadis S, Mamisashvili L, Ross L. Achieving the balance. Treating depressed pregnant women with antidepressants. J Clin Psych 2013; 74 (4): 375 – 376. 34- Grigoriadis S, Vonderporten E, Mamisashvili L, Eady A, Tomlinson G, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta analysis. J Clin Psych 2013; 74 (4): e309 – e 320. 35- Grigoriadis S, Vonderporten E, Mamisashvili L, Tomlinson G, Dennis C et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta analysis. J Clin Psych 2013; 74 (4): e321 – e 341. 36- Grigoriadis S, Vonderporten E, Mamisashvili L, Roerecke M, Rehm J, Dennis CL, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta analysis of the best evidence. J Cin Psychiatr 2013; 74 (4): e293 – e308. 37- Grote N, Bridge J, Gavin A, Melville J, Iyengar S et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight and intrauterine growth restriction. Arch Gen Psychiatry 2010; 67: 1012 – 1024. 38- Helbig A, Kaasen A, Malt U, Haugen G. Does antenatal maternal psychological distress affect placental circulation in the third trimester? Plos one 2013; 8 (2): e57071. 39- Henshaw C, Cox J, Barton J. Modern management of perinatal psychiatric disorders. R C Psych Publications, London, 2009. 40- Kinsella M, Monk C. Impact of maternal stress, depression and anxiety on fetal neurobehavioral development. Clin Obstet Gynecol 2009; 52: 425 – 440. 41- Koren G, Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol 2012; 157 – 163. 42- Liu D, Odouli R. Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Human Reproduction 2009; 24: 146 – 153. 43- Louik C, Lin A, Werler M, Hernández-Díaz S, Mitchell A. First-trimester use of selective serotonine-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675 – 2683. 44- Lupien S, McEwen B, Gunnar M, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nature 2009; 10: 434 – 445. 45- Lyell DJ, Chambers AS, Steidtmann D, et al. Antenatal identification of major depressive disorder: a cohort study. Am J Obstet Gynecol 2012;207:506.e1-6. 46- Malm H, Klaukka T, Neuvonen P. Risks associated with selective serotonin reuptake 34 // EDITORIAL SCIENS

Psicofarmacología 13:81, Agosto 2013 inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289 – 96. 47- Marroun H, Jaddoe V, Hudziak J, Roza S, Steegers E et al. Maternal use of selective serotonine reuptake inhibitors, fetal growth and risk of adverse birth outcomes. Arch Gen Psychiatry online, March 5, 2012, doi: 10.1001/archgenpsychiatry. 2011.2333. 48- Mazaira S. Efecto de los psicofármacos en el feto y el recién nacido. Vértex Rev Arg de Psiquiat 2005: XVI: 35 – 42. 49- Mazaira S. Tratamiento farmacológico de los trastornos psiquiátricos durante el embarazo y la lactancia. En: Wikinski – Jufe: El tratamiento farmacológico en Psiquiatría. Segunda Edición. Editorial Panamericana, Buenos Aires, 2013. 50- Mejías C, Rodríguez-Pinilla E, Fernández Martín P, Martínez Frías M. Efectos adversos de los inhibidores de la recaptación de serotonina durante el tercer trimestre de la gestación y guías de prevención. Med Clin (Barc) 2007; 128 (15): 584 – 589. 51- Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau R, Oberlander T. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 2006; 163: 1026 – 1032. 52- Moses-Kolko E, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner K. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. Literature review and implications for clinical applications. JAMA 2005; 293 (19): 2372 – 2383. 53- Nakai Pour H, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneus abortion. CMAJ 2010; DOI:10.1503 54- Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry 2002; 63 (suppl 7): 24-30. 55- Nulman I, Koren G, Rovet J, Barrera M, Pulver A et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonine reuptake inhibitors or untreated matrnal depression. Am J Psychiatry 2012; 169: 1165 – 1174. 56- Oberlander T, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898 – 906. 57- Parry B. Assessing risk and benefit: to treat or not to treat major depression during pregnancy with antidepressant medication. Am J Psychiatry 2009; 166 (5): 512 – 514. 58- Payne J, Meltzer Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol 2009; 52: 469 – 482. 59- Pearlstein T. Perinatal depression: treatment options and dilemmas. J Psychiatry Neurosci 2008; 33 (4): 302 – 318. 60- Pedersen LH, Henriksen TB, Bech BH, Licht RW, Kjaer D, Olsen J. Prenatal antidepressant exposure and behavioral problems in early childhood - a cohort study. Acta Psychiatr Scandinav 2013; 127:126 – 135. 61- Rai D, Lee B, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case control study. BMJ 2013; April, 346:12059. 62- Scottish Intercollegiate Guidelines Network (SIGN). Management of perinatal mood disorders. A national clinical guideline. Edinburgh, SIGN March 2012. 63- Steiner M. Prenatal exposure to antidepressants: how safe are they? Am J Psychiatry 2012; 169: 1131 – 1132. 64- Tyano S, Keren M, Herrman H, Cox J. Parenthood and mental health. A bridge between infant and adult psychiatry. Wiley – Blackwell, Chichester, UK, 2010. 65- Van den Vergh B, Mulder E, Mennes M, Glover V. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci Biobehav Rev 2005; 29: 237 – 258. 66- Viguera A, Tondo L, Koukopoulos A, Reginaldi D, Lepri B, Baldessarini R. Episodes o f Mood Disorders in 2252 Pregnancies and postpartum periods. Am J Psychiatry 2011; 168: 1179 – 1185. 67- Way C. Safety of newer antidepressants in pregnancy. Pharmacotherapy 2007; 27 (4): 546 – 552. 68- Wichman C, Moore K, Lang T, St Sauver J, Heise R, Watson W. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84 (1): 23 – 27. 69- Wisner K, Sit D, Hanusa B, Moses-Kolko E, Bogen D, Hunker D, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; AjA: 1 – 10. 70- Yonkers K. Parsing risk for the use of selective serotonine reuptake inhibitors in pregnancy. Am J Psychiatry 2009; 166 (3): 268 – 270. 71- Yonkers K. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psych 2009; 31: 403-413. EDITORIAL SCIENS // 35

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015